QUATTRO IN ACTION
ENDOCRINOLOGY + RADIOLOGY
What strategic actions can a company take to accelerate growth of its novel diagnostic tests for endocrine tumors?
COMPANY CEO + COO
A leading-edge molecular cytology company had developed a test based on RNA-sequencing to help physicians determine which patients would benefit from surgery to treat certain endocrine tumors.
The company’s business model included tests performed in both the hospital as well as the community and used processes to encourage reflexive testing. The CEO and senior team wanted to determine what actions could be taken with the different groups of customers to increase growth further.
Quattro built an analytic framework to quantify growth opportunities for the diagnostics tests by site of care and for every physician type.
The company could use the framework to prioritize major actions based on their ability to increase near-term test volume
Developed comprehensive set growth lever concepts across physician segments and sites of care.
Based on opportunities highlighted in the analytic framework, Quattro identified potential growth programs targeted at specific physician segments in specific sites of care.
Using hundreds of physician interviews and surveys, Quattro evaluated the impact from each growth lever idea among current and potential customers in the target segments. Quattro worked with the full senior management team to prioritize the resulting programs into an integrated overall growth strategy.